Découvrez nos professeurs et professeures!

Louis Lacombe

Directeur de département

Louis Lacombe
Centre de recherche sur le cancer
Centre de recherche du CHU de Québec - Université Laval
Partager la fiche :

Contribution à la recherche

Axe de recherche de l'Université Laval :

Santé et bien-être durables

Thématiques de recherche de la Faculté de médecine :

Immunologie-infectiologie
Oncologie

Domaines et intérêts de recherche du (de la) professeur(e) :

Cancer
  • Cancer de l'appareil urinaire
  • Tabagisme et cancer
  • Environnement et cancer
  • Cancer la prostate
  • Carcinogénèse
  • Diagnostic et détection du cancer
  • Apoptose et cancer
  • Cancers hormonaux-dépendants
Génétique humaine
  • Interactions gènes et environnement
  • Gènes de susceptibilité

Projets de recherche

  • Targeting sex steroids to improve the response to bladder cancer immunotherapy - Instituts de recherche en santé du Canada - Subvention Projet, co-chercheur - 2021-10-01 au 2026-09-30
  • Aberrant UGT2828 androgne inactivation pathway predict prostate cancer progression. - CHU de Québec – Université Laval – CHUL - Développement de la recherche (FC), chercheur principal - 2022-02-05 au 2025-03-30
  • Soutien à la recherche - Université Laval - Fonds internes, chercheur principal - 2017-07-01 au 2024-06-30
  • Aberrant UGT2B28 androgen inactivation pathway predicts prostate cancer progression - Société de recherche sur le cancer - Subvention de fonctionnement, co-chercheur - 2021-09-01 au 2023-08-31
  • The Contribution of Non-Classical 11-oxy Androgens to Prostate Cancer Progression - Cancer de la prostate Canada - Subvention de découverte, co-chercheur - 2019-04-01 au 2022-03-30
  • Interaction between environment, diet, physical activities, and sexual habits, in the risk of prostate cancer. Validation of biomarkers to personnalize preventive interventions. - Société de recherche sur le cancer - Compétition GRePEC (SRC/FRSQ/MDEIE), co-chercheur - 2012-10-01 au 2021-12-31

Publications

  • Effects of omega-3 fatty acids supplementation on perioperative blood loss and complications after radical prostatectomy, Samuel Fradet, Jean-François Pelletier, Narcisse Singbo, Louis Lacombe, Paul Toren, Michele Lodde, Thierry Dujardin, Rabi Tiguert, Yves Fradet, Karine Robitaille, Vincent Fradet, Clinical Nutrition ESPEN, 2022, 10.1016/j.clnesp.2021.12.011
  • Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer., Kourbanhoussen K, Joncas FH, D Wallis CJ, Hovington H, Dagenais F, Fradet Y, Guillemette C, Lacombe L, Toren P, Asian journal of andrology, 2022, 10.4103/aja.aja_58_21
  • Double inferior vena cava systems during retroperitoneal surgery: Description of a systematic approach to a rare and challenging anatomic variant., Chaud GJ, Lacombe L, Dagenais F, Journal of vascular surgery cases and innovative techniques, 2021, 10.1016/j.jvscit.2021.12.003
  • Résumés AUQ 2021., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7674
  • 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) is accurate for high-grade prostate cancer bone staging when compared to bone scintigraphy., Otis-Chapados S, Goulet CR, Dubois G, Lavallée É, Dujardin T, Fradet Y, Lacombe L, Lodde M, Tiguert R, Toren P, Fradet V, Beauregard JM, Buteau FA, Pouliot F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7107
  • Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Abridged version., Bhindi B, Kool R, Kulkarni GS, Siemens DR, Aprikian AG, Breau RH, Brimo F, Fairey A, French C, Hanna N, Izawa JI, Lacombe L, McPherson V, Rendon RA, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7487
  • Canadian Urological Association guideline on the management of non-muscle-invasive bladder cancer - Full-text., Bhindi B, Kool R, Kulkarni GS, Siemens DR, Aprikian AG, Breau RH, Brimo F, Fairey A, French C, Hanna N, Izawa JI, Lacombe L, McPherson V, Rendon RA, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2021, 10.5489/cuaj.7367
  • Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progression, Jean-Philippe Emond, Louis Lacombe, Patrick Caron, Véronique Turcotte, David Simonyan, Armen Aprikian, Fred Saad, Michel Carmel, Simone Chevalier, Chantal Guillemette, Eric Lévesque, British Journal of Cancer, 2021, 10.1038/s41416-021-01376-z
  • A prospective, multisite study analyzing the percentage of urological cases that can be completely managed by telemedicine., Turcotte B, Paquet S, Blais AS, Blouin AC, Bolduc S, Bureau M, Caumartin Y, Cloutier J, Deschênes-Rompré MP, Dujardin T, Fradet Y, Lacombe L, Pouliot F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020, 10.5489/cuaj.6862
  • Northeastern Section of the AUA 72nd Annual Meeting Abstracts, Donnelly L, Tang J, Lian F, Higgins P, Samarakoon R, Doersch K, Abston K, Kim H, Li X, Bjazevic J, Spierling A, Al K, Razvi H, Burton J, Bjazevic J, Skog J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer., Hussain M, Mateo J, Fizazi K, Saad F, Shore N, Sandhu S, Chi KN, Sartor O, Agarwal N, Olmos D, Thiery-Vuillemin A, Twardowski P, Roubaud G, PROfound Trial Investigators, The New England journal of medicine, 2020, 10.1056/nejmoa2022485
  • Achieving the "trifecta" with open versus minimally invasive partial nephrectomy., Ghavimi S, Saarela O, Pouliot F, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lavallee L, Lacombe L, Fairey A, Jewett M, Liu Z, Tanguay S, Black PC, World journal of urology, 2020, 10.1007/s00345-020-03349-y
  • Androgen receptor and immune cell PD-L1 expression in bladder tumors predicts disease recurrence and survival., Toren P, Brisson H, Simonyan D, Hovington H, Lacombe L, Bergeron A, Fradet Y, World journal of urology, 2020, 10.1007/s00345-020-03358-x
  • Message from our President, Zorn K, Bhojani N, Elterman D, Goldenberg S, So A, Paterson R, Desai M, Roehrborn R, Kaplan S, Gilling P, Berto F, Wang Z, Bjazevic J, Filler G, Romao R, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2020
  • Enzalutamide and Survival in Nonmetastatic, Castration-Resistant Prostate Cancer., Sternberg CN, Fizazi K, Saad F, Shore ND, De Giorgi U, Penson DF, Ferreira U, Efstathiou E, Madziarska K, Kolinsky MP, Cubero DIG, Noerby B, PROSPER Investigators, The New England journal of medicine, 2020, 10.1056/nejmoa2003892
  • Extragonadal Steroids Contribute Significantly to Androgen Receptor Activity and Development of Castration Resistance in Recurrent Prostate Cancer after Primary Therapy., Pouliot F, Rouleau M, Neveu B, Toren P, Morin F, Vélot L, Ding K, Caron P, Lacombe L, Lévesque É, Klotz L, Guillemette C, The Journal of urology, 2020, 10.1097/ju.0000000000000699
  • Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer., Shore ND, Saad F, Cookson MS, George DJ, Saltzstein DR, Tutrone R, Akaza H, Bossi A, van Veenhuyzen DF, Selby B, Fan X, Kang V, Walling J, Tombal B, HERO Study Investigators, The New England journal of medicine, 2020, 10.1056/nejmoa2004325
  • Alternative promoters control UGT2B17-dependent androgen catabolism in prostate cancer and its influence on progression., Lévesque E, Labriet A, Hovington H, Allain ÉP, Melo-Garcia L, Rouleau M, Brisson H, Turcotte V, Caron P, Villeneuve L, Leclercq M, Droit A, Guillemette C, British journal of cancer, 2020, 10.1038/s41416-020-0749-2
  • Best practices for enhancing surgical research: a perspective from the Canadian Association of Chairs of Surgical Research, Sener A, Anderson CC, Auger FA, Barralet J, Brindle M, Cayabyab FS, Fehlings MG, Lacombe L, Perrault LP, Sabbagh R, Seely AJ, Wallace C, Ellsmere J, Keijzer R, Canadian journal of surgery. Journal canadien de chirurgie, 2019, 10.1503/cjs.012619
  • Glucuronidation of Abiraterone and Its Pharmacologically Active Metabolites by UGT1A4, Influence of Polymorphic Variants and Their Potential as Inhibitors of Steroid Glucuronidation., Vaillancourt J, Turcotte V, Caron P, Villeneuve L, Lacombe L, Pouliot F, Lévesque É, Guillemette C, Drug metabolism and disposition: the biological fate of chemicals, 2019, 10.1124/dmd.119.088229
  • Genome-wide germline correlates of the epigenetic landscape of prostate cancer., Houlahan KE, Shiah YJ, Gusev A, Yuan J, Ahmed M, Shetty A, Ramanand SG, Yao CQ, Bell C, O'Connor E, Huang V, Fraser M, Heisler LE, Livingstone J, Boutros PC, Nature medicine, 2019, 10.1038/s41591-019-0579-z
  • Résumés AUQ 2019., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2019, 10.5489/cuaj.6229
  • Receipt of 5-Alpha Reductase Inhibitors Before Radical Cystectomy: Do They Render High-Grade Bladder Tumors Less Aggressive?, McMartin C, Lacombe L, Fradet V, Fradet Y, Lodde M, Toren P, Clinical genitourinary cancer, 2019, 10.1016/j.clgc.2019.07.016
  • The Immune Landscape of Cancer., Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Shmulevich I, Immunity, 2019, 10.1016/j.immuni.2019.08.004
  • Validation of the prognostic value of NF-κB p65 in prostate cancer: A retrospective study using a large multi-institutional cohort of the Canadian Prostate Cancer Biomarker Network., Grosset AA, Ouellet V, Caron C, Fragoso G, Barrès V, Delvoye N, Latour M, Aprikian A, Bergeron A, Chevalier S, Fazli L, Fleshner N, Gleave M, Canadian Prostate Cancer Biomarker Network, PLoS medicine, 2019, 10.1371/journal.pmed.1002847
  • Use and duration of antibiotic prophylaxis and the rate of urinary tract infection after radical cystectomy for bladder cancer: Results of a multicentric series., Haider M, Ladurner C, Mayr R, Tandogdu Z, Fritsche HM, Fradet V, Comploj E, Pycha A, Lemire F, Lacombe L, Fradet Y, Toren P, Lodde M, Urologic oncology, 2019, 10.1016/j.urolonc.2019.01.017
  • A Comprehensive Analysis of Steroid Hormones and Progression of Localized High-Risk Prostate Cancer., Lévesque E, Caron P, Lacombe L, Turcotte V, Simonyan D, Fradet Y, Aprikian A, Saad F, Carmel M, Chevalier S, Guillemette C, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2019, 10.1158/1055-9965.epi-18-1002
  • Discordance between testosterone measurement methods in castrated prostate cancer patients., Rouleau M, Lemire F, Déry M, Thériault B, Dubois G, Fradet Y, Toren P, Guillemette C, Lacombe L, Klotz L, Saad F, Guérette D, Pouliot F, Endocrine connections, 2019, 10.1530/ec-18-0476
  • Factors Affecting Interindividual Variability of Hepatic UGT2B17 Protein Expression Examined Using a Novel Specific Monoclonal Antibody., Émond JP, Labriet A, Desjardins S, Rouleau M, Villeneuve L, Hovington H, Brisson H, Lacombe L, Simonyan D, Caron P, Périgny M, Têtu B, Fallon JK, Lévesque E, Drug metabolism and disposition: the biological fate of chemicals, 2019, 10.1124/dmd.119.086330
  • Psychosocial adjustment to a prostate cancer diagnosis in a cohort of radical prostatectomy patients in Quebec, Canada., Wissing MD, Chevalier S, O'Flaherty A, McKercher G, Aprikian S, Saad F, Carmel M, Lacombe L, Hamel M, Aprikian A, Psycho-oncology, 2019, 10.1002/pon.5031
  • Widespread and Functional RNA Circularization in Localized Prostate Cancer., Chen S, Huang V, Xu X, Livingstone J, Soares F, Jeon J, Zeng Y, Hua JT, Petricca J, Guo H, Wang M, Yousif F, Zhang Y, Donmez N, Ahmed M, Volik S, He HH, Cell, 2019, 10.1016/j.cell.2019.01.025
  • Abstraits AUQ 2018, Naud E, Ramsay S, Moore K, Bolduc S, Rompré-Brodeur A, Ayoub M, Shinde S, Piccirilo C, Seuntjens J, Mansure J, Kassouf W, Lemire F, Rouleau M, Saad F, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • Comprehensive Molecular Characterization of the Hippo Signaling Pathway in Cancer., Wang Y, Xu X, Maglic D, Dill MT, Mojumdar K, Ng PK, Jeong KJ, Tsang YH, Moreno D, Bhavana VH, Peng X, Ge Z, Chen H, Li J, Chen Z, Zhang H, Han L, Liang H, Cell reports, 2018, 10.1016/j.celrep.2018.10.001
  • A Pan-Cancer Analysis Reveals High-Frequency Genetic Alterations in Mediators of Signaling by the TGF-β Superfamily., Korkut A, Zaidi S, Kanchi RS, Rao S, Gough NR, Schultz A, Li X, Lorenzi PL, Berger AC, Robertson G, Kwong LN, Datto M, Roszik J, Ling S, Ravikumar V, Akbani R, Cell systems, 2018, 10.1016/j.cels.2018.08.010
  • Optimization of the 2014 Gleason grade grouping in a Canadian cohort of patients with localized prostate cancer., Wissing M, Brimo F, Chevalier S, Scarlata E, McKercher G, O'Flaherty A, Aprikian S, Thibodeau V, Saad F, Carmel M, Lacombe L, Têtu B, Aprikian A, BJU international, 2018, 10.1111/bju.14512
  • The Terry Fox Research Institute Canadian Prostate Cancer Biomarker Network: an analysis of a pan-Canadian multi-center cohort for biomarker validation., Ouellet V, Aprikian A, Bergeron A, Brimo F, Bristow RG, Chevalier S, Drachenberg D, Fazli L, Fleshner NE, Gleave M, Karakiewicz P, Klotz L, Saad F, BMC urology, 2018, 10.1186/s12894-018-0392-x
  • Comprehensive Analysis of Alternative Splicing Across Tumors from 8,705 Patients., Kahles A, Lehmann KV, Toussaint NC, Hüser M, Stark SG, Sachsenberg T, Stegle O, Kohlbacher O, Sander C, Cancer Genome Atlas Research Network, Rätsch G, Cancer cell, 2018, 10.1016/j.ccell.2018.07.001
  • Comprehensive Characterization of Cancer Driver Genes and Mutations., Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Kwok-Shing Ng P, Jeong KJ, Ding L, Cell, 2018, 10.1016/j.cell.2018.07.034
  • The relationship between body-mass index, physical activity, and pathologic and clinical outcomes after radical prostatectomy for prostate cancer., Wissing M, Chevalier S, McKercher G, Laprise C, Aprikian S, O'Flaherty A, Scarlata E, Saad F, Carmel M, Lacombe L, Brimo F, Latour M, Aprikian A, World journal of urology, 2018, 10.1007/s00345-018-2457-6
  • 2018 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018
  • Contemporary outcomes of palliative transurethral resection of the prostate in patients with locally advanced prostate cancer., Pelletier J, Cyr SJ, Julien AS, Fradet Y, Lacombe L, Toren P, Urologic oncology, 2018, 10.1016/j.urolonc.2018.05.004
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma., Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Linehan WM, Cell reports, 2018, 10.1016/j.celrep.2018.06.032
  • A Comprehensive Pan-Cancer Molecular Study of Gynecologic and Breast Cancers., Berger AC, Korkut A, Kanchi RS, Hegde AM, Lenoir W, Liu W, Liu Y, Fan H, Shen H, Ravikumar V, Rao A, Schultz A, Li X, Sumazin P, Williams C, Akbani R, Cancer cell, 2018, 10.1016/j.ccell.2018.03.014
  • A Multi-Institutional Validation of Gleason Score Derived from Tissue Microarray Cores., Leyh-Bannurah SR, Trudel D, Latour M, Zaffuto E, Grosset AA, Tam C, Ouellet V, Graefen M, Budäus L, Aprikian AG, Lacombe L, Fleshner NE, Gleave ME, Karakiewicz PI, Pathology oncology research : POR, 2018, 10.1007/s12253-018-0408-6
  • A Pan-Cancer Analysis of Enhancer Expression in Nearly 9000 Patient Samples., Chen H, Li C, Peng X, Zhou Z, Weinstein JN, Cancer Genome Atlas Research Network, Liang H, Cell, 2018, 10.1016/j.cell.2018.03.027
  • An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics., Liu J, Lichtenberg T, Hoadley KA, Poisson LM, Lazar AJ, Cherniack AD, Kovatich AJ, Benz CC, Levine DA, Lee AV, Omberg L, Wolf DM, Shriver CD, Hu H, Cell, 2018, 10.1016/j.cell.2018.02.052
  • Cell-of-Origin Patterns Dominate the Molecular Classification of 10,000 Tumors from 33 Types of Cancer., Hoadley KA, Yau C, Hinoue T, Wolf DM, Lazar AJ, Drill E, Shen R, Taylor AM, Cherniack AD, Thorsson V, Akbani R, Bowlby R, Wong CK, Wiznerowicz M, Laird PW, Cell, 2018, 10.1016/j.cell.2018.03.022
  • Comparative Molecular Analysis of Gastrointestinal Adenocarcinomas., Liu Y, Sethi NS, Hinoue T, Schneider BG, Cherniack AD, Sanchez-Vega F, Seoane JA, Farshidfar F, Bowlby R, Islam M, Kim J, Chatila W, Akbani R, Laird PW, Cancer cell, 2018, 10.1016/j.ccell.2018.03.010
  • Comprehensive Characterization of Cancer Driver Genes and Mutations., Bailey MH, Tokheim C, Porta-Pardo E, Sengupta S, Bertrand D, Weerasinghe A, Colaprico A, Wendl MC, Kim J, Reardon B, Ng PK, Jeong KJ, Cao S, Wang Z, Ding L, Cell, 2018, 10.1016/j.cell.2018.02.060
  • Driver Fusions and Their Implications in the Development and Treatment of Human Cancers., Gao Q, Liang WW, Foltz SM, Mutharasu G, Jayasinghe RG, Cao S, Liao WW, Reynolds SM, Wyczalkowski MA, Yao L, Yu L, Sun SQ, Ding L, Cell reports, 2018, 10.1016/j.celrep.2018.03.050
  • Genomic and Functional Approaches to Understanding Cancer Aneuploidy., Taylor AM, Shih J, Ha G, Gao GF, Zhang X, Berger AC, Schumacher SE, Wang C, Hu H, Liu J, Lazar AJ, Cancer Genome Atlas Research Network, Meyerson M, Cancer cell, 2018, 10.1016/j.ccell.2018.03.007
  • Genomic and Molecular Landscape of DNA Damage Repair Deficiency across The Cancer Genome Atlas., Knijnenburg TA, Wang L, Zimmermann MT, Chambwe N, Gao GF, Cherniack AD, Fan H, Shen H, Way GP, Greene CS, Liu Y, Akbani R, Feng B, Donehower LA, Wang C, Cell reports, 2018, 10.1016/j.celrep.2018.03.076
  • Genomic, Pathway Network, and Immunologic Features Distinguishing Squamous Carcinomas., Campbell JD, Yau C, Bowlby R, Liu Y, Brennan K, Fan H, Taylor AM, Wang C, Walter V, Akbani R, Byers LA, Creighton CJ, Coarfa C, Shih J, Cherniack AD, Van Waes C, Cell reports, 2018, 10.1016/j.celrep.2018.03.063
  • Integrated Genomic Analysis of the Ubiquitin Pathway across Cancer Types., Ge Z, Leighton JS, Wang Y, Peng X, Chen Z, Chen H, Sun Y, Yao F, Li J, Zhang H, Liu J, Shriver CD, Hu H, Cancer Genome Atlas Research Network, Liang H, Cell reports, 2018, 10.1016/j.celrep.2018.03.047
  • lncRNA Epigenetic Landscape Analysis Identifies EPIC1 as an Oncogenic lncRNA that Interacts with MYC and Promotes Cell-Cycle Progression in Cancer., Wang Z, Yang B, Zhang M, Guo W, Wu Z, Wang Y, Jia L, Li S, Cancer Genome Atlas Research Network, Xie W, Yang D, Cancer cell, 2018, 10.1016/j.ccell.2018.03.006
  • Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas., Way GP, Sanchez-Vega F, La K, Armenia J, Chatila WK, Luna A, Sander C, Cherniack AD, Mina M, Ciriello G, Schultz N, Greene CS, Cell reports, 2018, 10.1016/j.celrep.2018.03.046
  • Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation., Malta TM, Sokolov A, Gentles AJ, Burzykowski T, Poisson L, Weinstein JN, Kamińska B, Huelsken J, Omberg L, Gevaert O, Colaprico A, Czerwińska P, Wiznerowicz M, Cell, 2018, 10.1016/j.cell.2018.03.034
  • Molecular Characterization and Clinical Relevance of Metabolic Expression Subtypes in Human Cancers., Peng X, Chen Z, Farshidfar F, Xu X, Lorenzi PL, Wang Y, Cheng F, Tan L, Mojumdar K, Du D, Ge Z, Li J, Thomas GV, Birsoy K, Liu L, Zhang H, Zhao Z, Liang H, Cell reports, 2018, 10.1016/j.celrep.2018.03.077
  • Oncogenic Signaling Pathways in The Cancer Genome Atlas., Sanchez-Vega F, Mina M, Armenia J, Chatila WK, Luna A, La KC, Dimitriadoy S, Liu DL, Kantheti HS, Saghafinia S, Chakravarty D, Daian F, Gao Q, Schultz N, Cell, 2018, 10.1016/j.cell.2018.03.035
  • Pan-Cancer Analysis of lncRNA Regulation Supports Their Targeting of Cancer Genes in Each Tumor Context., Chiu HS, Somvanshi S, Patel E, Chen TW, Singh VP, Zorman B, Patil SL, Pan Y, Chatterjee SS, Cancer Genome Atlas Research Network, Sood AK, Sumazin P, Cell reports, 2018, 10.1016/j.celrep.2018.03.064
  • Pathogenic Germline Variants in 10,389 Adult Cancers., Huang KL, Mashl RJ, Wu Y, Ritter DI, Wang J, Oh C, Paczkowska M, Reynolds S, Wyczalkowski MA, Oak N, Scott AD, Krassowski M, Cherniack AD, Ding L, Cell, 2018, 10.1016/j.cell.2018.03.039
  • Perspective on Oncogenic Processes at the End of the Beginning of Cancer Genomics., Ding L, Bailey MH, Porta-Pardo E, Thorsson V, Colaprico A, Bertrand D, Gibbs DL, Weerasinghe A, Huang KL, Tokheim C, Cortés-Ciriano I, Jayasinghe R, Cancer Genome Atlas Research Network, Cell, 2018, 10.1016/j.cell.2018.03.033
  • Somatic Mutational Landscape of Splicing Factor Genes and Their Functional Consequences across 33 Cancer Types., Seiler M, Peng S, Agrawal AA, Palacino J, Teng T, Zhu P, Smith PG, Cancer Genome Atlas Research Network, Buonamici S, Yu L, Cell reports, 2018, 10.1016/j.celrep.2018.01.088
  • Spatial Organization and Molecular Correlation of Tumor-Infiltrating Lymphocytes Using Deep Learning on Pathology Images., Saltz J, Gupta R, Hou L, Kurc T, Singh P, Nguyen V, Samaras D, Shroyer KR, Zhao T, Batiste R, Van Arnam J, Cancer Genome Atlas Research Network, Thorsson V, Cell reports, 2018, 10.1016/j.celrep.2018.03.086
  • Surveillance guidelines based on recurrence patterns for upper tract urothelial carcinoma., Locke JA, Hamidizadeh R, Kassouf W, Rendon RA, Bell D, Izawa J, Chin J, Kapoor A, Shayegen B, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey AS, Black PC, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2018, 10.5489/cuaj.5377
  • Systematic Analysis of Splice-Site-Creating Mutations in Cancer., Jayasinghe RG, Cao S, Gao Q, Wendl MC, Vo NS, Reynolds SM, Zhao Y, Climente-González H, Chai S, Wang F, Varghese R, Huang M, Liang WW, Ding L, Cell reports, 2018, 10.1016/j.celrep.2018.03.052
  • The Cancer Genome Atlas Comprehensive Molecular Characterization of Renal Cell Carcinoma., Ricketts CJ, De Cubas AA, Fan H, Smith CC, Lang M, Reznik E, Bowlby R, Gibb EA, Akbani R, Beroukhim R, Bottaro DP, Choueiri TK, Gibbs RA, Godwin AK, Linehan WM, Cell reports, 2018, 10.1016/j.celrep.2018.03.075
  • The Immune Landscape of Cancer., Thorsson V, Gibbs DL, Brown SD, Wolf D, Bortone DS, Ou Yang TH, Porta-Pardo E, Gao GF, Plaisier CL, Eddy JA, Ziv E, Culhane AC, Paull EO, Shmulevich I, Immunity, 2018, 10.1016/j.immuni.2018.03.023
  • Increased Prostate Cancer Glucose Metabolism Detected by 18F-fluorodeoxyglucose Positron Emission Tomography/Computed Tomography in Localised Gleason 8-10 Prostate Cancers Identifies Very High-risk Patients for Early Recurrence and Resistance to Castration., Lavallée E, Bergeron M, Buteau FA, Blouin AC, Duchesnay N, Dujardin T, Tiguert R, Lacombe L, Fradet V, Makao-Nguile M, Fradet Y, Beauregard JM, Pouliot F, European urology focus, 2018, 10.1016/j.euf.2018.03.008
  • Pan-cancer Alterations of the MYC Oncogene and Its Proximal Network across the Cancer Genome Atlas., Schaub FX, Dhankani V, Berger AC, Trivedi M, Richardson AB, Shaw R, Zhao W, Zhang X, Ventura A, Liu Y, Ayer DE, Hurlin PJ, Cherniack AD, Eisenman RN, Cancer Genome Atlas Network, Cell systems, 2018, 10.1016/j.cels.2018.03.003
  • Scalable Open Science Approach for Mutation Calling of Tumor Exomes Using Multiple Genomic Pipelines., Ellrott K, Bailey MH, Saksena G, Covington KR, Kandoth C, Stewart C, Hess J, Ma S, Chiotti KE, McLellan M, Sofia HJ, Hutter C, Getz G, Wheeler D, Cancer Genome Atlas Research Network, Cell systems, 2018, 10.1016/j.cels.2018.03.002
  • Apalutamide Treatment and Metastasis-free Survival in Prostate Cancer., Smith MR, Saad F, Chowdhury S, Oudard S, Hadaschik BA, Graff JN, Olmos D, Mainwaring PN, Lee JY, Uemura H, Lopez-Gitlitz A, Trudel GC, Espina BM, SPARTAN Investigators, The New England journal of medicine, 2018, 10.1056/nejmoa1715546
  • Preoperative nutritional factors and outcomes after radical cystectomy: A narrative review., Allaire J, Ben-Zvi T, Lamarche B, Robitaille K, Fradet Y, Lacombe L, Fradet V, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4471
  • ABSTRAITS AUQ 2017., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4968
  • Prognostic value of urinary prostate cancer antigen 3 (PCA3) during active surveillance of patients with low-risk prostate cancer receiving 5α-reductase inhibitors., Fradet V, Toren P, Nguile-Makao M, Lodde M, Lévesque J, Léger C, Caron A, Bergeron A, Ben-Zvi T, Lacombe L, Pouliot F, Tiguert R, Dujardin T, Fradet Y, BJU international, 2017, 10.1111/bju.14041
  • Prospective Evaluation of Nutritional Factors to Predict the Risk of Complications for Patients Undergoing Radical Cystectomy: A Cohort Study., Allaire J, Léger C, Ben-Zvi T, Nguilé-Makao M, Fradet Y, Lacombe L, Fradet V, Nutrition and cancer, 2017, 10.1080/01635581.2017.1367941
  • 2017 NSAUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4896
  • 2017 CUA Abstracts, Klotz L, Loblaw A, Chin J, Fleshner N, Kebabdjian M, Pond G, Haider M, Briollais L, Ozcelik H, Xu J, Kwiatkowski M, Lalonde E, Sendorek D, Recker F, Braga L, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017
  • Positive surgical margins during partial nephrectomy for renal cell carcinoma: Results from Canadian Kidney Cancer information system (CKCis) collaborative., Bansal RK, Tanguay S, Finelli A, Rendon R, Moore RB, Breau RH, Lacombe L, Black PC, Kawakami J, Drachenberg D, Pautler S, Saarela O, Liu Z, Jewett MAS, Kapoor A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2017, 10.5489/cuaj.4264
  • A Prostate Cancer "Nimbosus": Genomic Instability and SChLAP1 Dysregulation Underpin Aggression of Intraductal and Cribriform Subpathologies., Chua MLK, Lo W, Pintilie M, Murgic J, Lalonde E, Bhandari V, Mahamud O, Gopalan A, Kweldam CF, van Leenders GJLH, Verhoef EI, Hoogland AM, Bristow RG, European urology, 2017, 10.1016/j.eururo.2017.04.034
  • Erratum to "The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System" [Urol Oncol 34(11) (2016) 486.e1-486.e7]., Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA, Urologic oncology, 2017, 10.1016/j.urolonc.2017.01.018
  • Metabolic Imaging of Prostate Cancer Reveals Intrapatient Intermetastasis Response Heterogeneity to Systemic Therapy., Morin F, Beauregard JM, Bergeron M, Nguile Makao M, Lacombe L, Fradet V, Fradet Y, Pouliot F, European urology focus, 2017, 10.1016/j.euf.2017.02.007
  • Genomic hallmarks of localized, non-indolent prostate cancer., Fraser M, Sabelnykova VY, Yamaguchi TN, Heisler LE, Livingstone J, Huang V, Shiah YJ, Yousif F, Lin X, Masella AP, Fox NS, Xie M, Prokopec SD, Boutros PC, Nature, 2017, 10.1038/nature20788
  • Quality indicators in the management of bladder cancer: A modified Delphi study., Khare SR, Aprikian A, Black P, Blais N, Booth C, Brimo F, Chin J, Chung P, Drachenberg D, Eapen L, Fairey A, Fleshner N, Fradet Y, Gotto G, Izawa J, Kassouf W, Urologic oncology, 2017, 10.1016/j.urolonc.2016.12.003
  • Translating a Prognostic DNA Genomic Classifier into the Clinic: Retrospective Validation in 563 Localized Prostate Tumors., Lalonde E, Alkallas R, Chua MLK, Fraser M, Haider S, Meng A, Zheng J, Yao CQ, Picard V, Orain M, Hovington H, Murgic J, Berlin A, Lacombe L, Boutros PC, European urology, 2016, 10.1016/j.eururo.2016.10.013
  • Tn-MUC1 DC Vaccination of Rhesus Macaques and a Phase I/II Trial in Patients with Nonmetastatic Castrate-Resistant Prostate Cancer., Scheid E, Major P, Bergeron A, Finn OJ, Salter RD, Eady R, Yassine-Diab B, Favre D, Peretz Y, Landry C, Hotte S, Mukherjee SD, Dekaban GA, Fink C, Foley R, Cancer immunology research, 2016, 10.1158/2326-6066.cir-15-0189
  • Disease progression and kidney function after partial vs. radical nephrectomy for T1 renal cancer., Forbes CM, Rendon RA, Finelli A, Kapoor A, Moore RB, Breau RH, Lacombe L, Kawakami J, Drachenberg DE, Pautler SE, Jewett MMA, Saarela O, Liu Z, Black PC, Urologic oncology, 2016, 10.1016/j.urolonc.2016.05.034
  • A Simple Variable Number of Tandem Repeat-Based Genotyping Strategy for the Detection of Handling Errors and Validation of Sample Identity in Biobanks., Pellerin C, McKercher G, Aprikian AG, Saad F, Lacombe L, Carmel M, Chevalier S, Biopreservation and biobanking, 2016, 10.1089/bio.2015.0113
  • The natural history of renal function after surgical management of renal cell carcinoma: Results from the Canadian Kidney Cancer Information System., Mason R, Kapoor A, Liu Z, Saarela O, Tanguay S, Jewett M, Finelli A, Lacombe L, Kawakami J, Moore R, Morash C, Black P, Rendon RA, Urologic oncology, 2016, 10.1016/j.urolonc.2016.05.025
  • Pathological Upstaging of Clinical T1 to Pathological T3a Renal Cell Carcinoma: A Multi-institutional Analysis of Short-term Outcomes., Nayak JG, Patel P, Saarela O, Liu Z, Kapoor A, Finelli A, Tanguay S, Rendon R, Moore R, Black PC, Lacombe L, Breau RH, Kawakami J, Drachenberg DE, Urology, 2016, 10.1016/j.urology.2016.03.029
  • Renal cell carcinoma with thrombus extending to the hepatic veins or right atrium: operative strategies based on 41 consecutive patients., Gagné-Loranger M, Lacombe L, Pouliot F, Fradet V, Dagenais F, European journal of cardio-thoracic surgery : official journal of the European Association for Cardio-thoracic Surgery, 2016, 10.1093/ejcts/ezw023
  • Abstraits AUQ 2016 Programme Scientifique - Session 1, Ramsay* S, Nadeau G, Moore K, Bolduc S, Shamout* S, Biardeau X, Corcos J, Campeau L, Clairefond* S, Ouellet V, Péant B, Barrès V, Fragoso G, Gebhart J, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Podium Session 1: Prostate Cancer June 26, 2016 1050–1150, Siemens D, Klotz H, Heidenreich A, Chowdhury S, Villers A, Baron B, van Os S, Hasabou N, Wang F, Forer D, Shore N, Timilshina N, Ouellet V, Gleave M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2016
  • Phase II Drug-Metabolizing Polymorphisms and Smoking Predict Recurrence of Non-Muscle-Invasive Bladder Cancer: A Gene-Smoking Interaction., Lacombe L, Fradet V, Lévesque É, Pouliot F, Larue H, Bergeron A, Hovington H, Caron A, Nguile-Makao M, Harvey M, Fradet Y, Guillemette C, Cancer prevention research (Philadelphia, Pa.), 2015, 10.1158/1940-6207.capr-15-0069
  • The Molecular Taxonomy of Primary Prostate Cancer., Cancer Genome Atlas Research Network, Cell, 2015, 10.1016/j.cell.2015.10.025
  • CUA guidelines on the management of non-muscle invasive bladder cancer., Kassouf W, Traboulsi SL, Kulkarni GS, Breau RH, Zlotta A, Fairey A, So A, Lacombe L, Rendon R, Aprikian AG, Siemens DR, Izawa JI, Black P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.3320
  • The UGT2B28 Sex-steroid Inactivation Pathway Is a Regulator of Steroidogenesis and Modifies the Risk of Prostate Cancer Progression., Belledant A, Hovington H, Garcia L, Caron P, Brisson H, Villeneuve L, Simonyan D, Têtu B, Fradet Y, Lacombe L, Guillemette C, Lévesque E, European urology, 2015, 10.1016/j.eururo.2015.06.054
  • Comparison of digital image analysis and visual scoring of KI-67 in prostate cancer prognosis after prostatectomy., Desmeules P, Hovington H, Nguilé-Makao M, Léger C, Caron A, Lacombe L, Fradet Y, Têtu B, Fradet V, Diagnostic pathology, 2015, 10.1186/s13000-015-0294-0
  • Canadian guidelines for the management of small renal masses (SRM)., Jewett MA, Rendon R, Lacombe L, Karakiewicz PI, Tanguay S, Kassouf W, Leveridge M, Cagiannos I, Kapoor A, Pautler S, Drachtenberg D, Moore R, Finelli A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.2969
  • CSF1 receptor targeting in prostate cancer reverses macrophage-mediated resistance to androgen blockade therapy., Escamilla J, Schokrpur S, Liu C, Priceman SJ, Moughon D, Jiang Z, Pouliot F, Magyar C, Sung JL, Xu J, Deng G, West BL, Bollag G, Fradet Y, Lacombe L, Wu L, Cancer research, 2015, 10.1158/0008-5472.can-14-0992
  • FDG-PET/CT for pre-operative staging and prognostic stratification of patients with high-grade prostate cancer at biopsy., Beauregard JM, Blouin AC, Fradet V, Caron A, Fradet Y, Lemay C, Lacombe L, Dujardin T, Tiguert R, Rimac G, Bouchard F, Pouliot F, Cancer imaging : the official publication of the International Cancer Imaging Society, 2015, 10.1186/s40644-015-0038-0
  • Surgical management of stage T1 renal tumours at Canadian academic centres., Lavallée LT, Tanguay S, Jewett MA, Wood L, Kapoor A, Rendon RA, Moore RB, Lacombe L, Kawakami J, Pautler SE, Drachenberg DE, Black PC, Lattouf JB, Breau RH, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015, 10.5489/cuaj.2598
  • 2015 CUA Abstracts, Power N, Willie C, Mazzola C, Tailly T, Sonke E, Pardhan S, Tram A, Brugarolas J, Sener A, Chambers A, Pautler S, Leong H, Punjani N, Power N, Kulkarni S, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2015
  • Low level of the X-linked ribosomal protein S4 in human urothelial carcinomas is associated with a poor prognosis., Paquet ÉR, Hovington H, Brisson H, Lacombe C, Larue H, Têtu B, Lacombe L, Fradet Y, Lebel M, Biomarkers in medicine, 2015, 10.2217/bmm.14.115
  • The UGT1 locus is a determinant of prostate cancer recurrence after prostatectomy., Laverdière I, Flageole C, Audet-Walsh É, Caron P, Fradet Y, Lacombe L, Lévesque É, Guillemette C, Endocrine-related cancer, 2014, 10.1530/erc-14-0423
  • The impact of method of distal ureter management during radical nephroureterectomy on tumour recurrence., Kapoor A, Dason S, Allard CB, Shayegan B, Lacombe L, Rendon R, Jacobsen NE, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014, 10.5489/cuaj.1985
  • Cystatin C for early detection of acute kidney injury after laparoscopic partial nephrectomy., Alesawi A, Nadeau G, Bergeron A, Dujardin T, Lacombe L, Caumartin Y, Urology annals, 2014, 10.4103/0974-7796.140988
  • Conditional survival after radical nephroureterectomy for upper tract carcinoma., Ploussard G, Xylinas E, Lotan Y, Novara G, Margulis V, Rouprêt M, Matsumoto K, Karakiewicz PI, Montorsi F, Remzi M, Seitz C, Scherr DS, Kapoor A, Kassouf W, European urology, 2014, 10.1016/j.eururo.2014.08.003
  • Enzalutamide in metastatic prostate cancer before chemotherapy., Beer TM, Armstrong AJ, Rathkopf DE, Loriot Y, Sternberg CN, Higano CS, Iversen P, Bhattacharya S, Carles J, Chowdhury S, Davis ID, de Bono JS, PREVAIL Investigators, The New England journal of medicine, 2014, 10.1056/nejmoa1405095
  • Risk factors for bladder cancer recurrence after nephroureterectomy for upper tract urothelial tumors: results from the Canadian Upper Tract Collaboration., Fradet V, Mauermann J, Kassouf W, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Tanguay S, Chin J, So A, Lattouf JB, Bell D, Saad F, Lacombe L, Urologic oncology, 2014, 10.1016/j.urolonc.2014.04.006
  • Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer., Huang SP, Lévesque E, Guillemette C, Yu CC, Huang CY, Lin VC, Chung IC, Chen LC, Laverdière I, Lacombe L, Fradet Y, Chang TY, Lee HZ, Juang SH, Bao BY, International journal of cancer, 2014, 10.1002/ijc.28904
  • Steroidogenic germline polymorphism predictors of prostate cancer progression in the estradiol pathway., Lévesque E, Laverdière I, Audet-Walsh E, Caron P, Rouleau M, Fradet Y, Lacombe L, Guillemette C, Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, 10.1158/1078-0432.ccr-13-2567
  • 2014 CUA Abstracts, Richard P, Bhatt J, Jewett M, Komisarenko M, Kachura J, Evans A, Finelli A, Mason R, Tanguay S, Liu Z, Kapoor A, Black P, Moore R, Morash C, Davies T, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014
  • Complete Penile Necrosis in a Patient With Heparin-induced Thrombocytopenia: A Case Report., Blais AS, Deschênes Rompré MP, Lacombe L, Urology case reports, 2014, 10.1016/j.eucr.2013.12.003
  • Congrés Annuel : Programme général Association des Urologues du Québec, Benjamin *, Melina A, Lateef A, Jennifer K, Anne-Marie M, Thomas G, Fred S, Bouchard *, Orabi H, Morissette A, Taillon G, Rousseau A, Bernard G, Delouya G, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2014
  • Effect of body mass index on the outcomes of patients with upper and lower urinary tract cancers treated by radical surgery: results from a Canadian multicenter collaboration., Bachir BG, Aprikian AG, Izawa JI, Chin JL, Fradet Y, Fairey A, Estey E, Jacobsen N, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Kapoor A, Kassouf W, Urologic oncology, 2014, 10.1016/j.urolonc.2013.10.016
  • Impact of concomitant carcinoma in situ on upstaging and outcome following radical cystectomy for bladder cancer., Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Saad F, Bell D, Drachenberg D, Kassouf W, World journal of urology, 2013, 10.1007/s00345-013-1207-z
  • Importance of 5α-reductase gene polymorphisms on circulating and intraprostatic androgens in prostate cancer., Lévesque É, Laverdière I, Lacombe L, Caron P, Rouleau M, Turcotte V, Têtu B, Fradet Y, Guillemette C, Clinical cancer research : an official journal of the American Association for Cancer Research, 2013, 10.1158/1078-0432.ccr-13-1100
  • Regional differences in practice patterns and outcomes in patients treated with radical cystectomy in a universal healthcare system., Bachir BG, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013, 10.5489/cuaj.201
  • Strategies for biochemical and pathologic quality assurance in a large multi-institutional biorepository; The experience of the PROCURE Quebec Prostate Cancer Biobank., Brimo F, Aprikian A, Latour M, Têtu B, Doueik A, Scarlata E, Hamel L, McKercher G, Saad F, Lacombe L, Carmel M, Chevalier S, Biopreservation and biobanking, 2013, 10.1089/bio.2013.0025
  • Comorbidity status does not independently predict survival outcomes after radical nephroureterectomy for upper tract urothelial carcinoma., Fairey AS, Jacobsen NE, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Kassouf W, European urology, 2013, 10.1016/j.eururo.2013.06.014
  • Adjuvant chemotherapy for upper-tract urothelial carcinoma treated with nephroureterectomy: assessment of adequate renal function and influence on outcome., Yafi FA, Tanguay S, Rendon R, Jacobsen N, Fairey A, Izawa J, Kapoor A, Black P, Lacombe L, Chin J, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Kassouf W, Urologic oncology, 2013, 10.1016/j.urolonc.2012.11.014
  • Multifocality rather than tumor location is a prognostic factor in upper tract urothelial carcinoma., Williams AK, Kassouf W, Chin J, Rendon R, Jacobsen N, Fairey A, Kapoor A, Black P, Lacombe L, Tanguay S, So A, Lattouf JB, Bell D, Fradet Y, Saad F, Izawa JI, Urologic oncology, 2013, 10.1016/j.urolonc.2011.12.004
  • Abstraits AUQ 2013, Trudeau V, Becker A, Roghmann F, Shariat S, Kluth L, Hanna N, Abdo A, Gandaglia G, Tian Z, Perrotte P, Trinh Q, Karakiewicz P, Sun M, Aharony S, Haddad R, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2013
  • Natural history of pT3-4 or node positive bladder cancer treated with radical cystectomy and no neoadjuvant chemotherapy in a contemporary North-American multi-institutional cohort., Power NE, Kassouf W, Bell D, Aprikian AG, Fradet Y, Lacombe L, Chin J, Izawa J, Estey E, Fairey A, Cagiannos I, Lattouf JB, Drachenberg D, Rendon RA, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11012
  • Regional differences in practice patterns and associated outcomes for upper tract urothelial carcinoma in Canada., Metcalfe M, Kassouf W, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Lattouf JB, Saad F, Lacombe L, Fradet Y, Fairey A, Jacobson NE, Black P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.12146
  • Comparison of oncological outcomes for open and laparoscopic radical nephroureterectomy: results from the Canadian Upper Tract Collaboration., Fairey AS, Kassouf W, Estey E, Tanguay S, Rendon R, Bell D, Izawa J, Chin J, Kapoor A, Matsumoto E, Black P, So A, Lattouf JB, Saad F, Drachenberg D, Jacobsen NE, BJU international, 2012, 10.1111/j.1464-410x.2012.11474.x
  • Molecular markers in key steroidogenic pathways, circulating steroid levels, and prostate cancer progression., Lévesque É, Huang SP, Audet-Walsh É, Lacombe L, Bao BY, Fradet Y, Laverdière I, Rouleau M, Huang CY, Yu CC, Caron P, Guillemette C, Clinical cancer research : an official journal of the American Association for Cancer Research, 2012, 10.1158/1078-0432.ccr-12-2812
  • A phase 3, double-blind, randomised, parallel-group, placebo-controlled study of oral weekly alendronate for the prevention of androgen deprivation bone loss in nonmetastatic prostate cancer: the Cancer and Osteoporosis Research with Alendronate and Leuprolide (CORAL) study., Klotz LH, McNeill IY, Kebabdjian M, Zhang L, Chin JL, Canadian Urology Research Consortium, European urology, 2012, 10.1016/j.eururo.2012.09.007
  • Increased survival with enzalutamide in prostate cancer after chemotherapy., Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, AFFIRM Investigators, The New England journal of medicine, 2012, 10.1056/nejmoa1207506
  • Northeastern Section of the American Urological Association 64(th) Annual Meeting, Niagara Falls, Ontario Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • The impact of solitary and multiple positive surgical margins on hard clinical end points in 1712 adjuvant treatment-naive pT2-4 N0 radical prostatectomy patients., Mauermann J, Fradet V, Lacombe L, Dujardin T, Tiguert R, Tetu B, Fradet Y, European urology, 2012, 10.1016/j.eururo.2012.08.002
  • 2012 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012
  • Outcomes of pT0N0 at radical cystectomy: The Canadian Bladder Cancer Network experience., Sandhu GS, Aprikian A, Chin J, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Kassouf W, Drachenberg D, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2012, 10.5489/cuaj.11276
  • Surveillance guidelines based on recurrence patterns after radical cystectomy for bladder cancer: the Canadian Bladder Cancer Network experience., Yafi FA, Aprikian AG, Fradet Y, Chin JL, Izawa J, Rendon R, Estey E, Fairey A, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Saad F, Drachenberg D, Kassouf W, BJU international, 2012, 10.1111/j.1464-410x.2012.11133.x
  • Radical cystectomyfor clinically muscle invasive bladder cancer: does prior non-invasive disease affect clinical outcome, , 2012
  • The contemporary role of lymph node dissection during nephroureterectomy in the management of upper urinary tract urothelial carcinoma: the Canadian experience., Mason RJ, Kassouf W, Bell DG, Lacombe L, Kapoor A, Jacobsen N, Fairey A, Izawa J, Black P, Tanguay S, Chin J, So A, Lattouf JB, Saad F, Matsumoto E, Rendon RA, Urology, 2012, 10.1016/j.urology.2011.11.058
  • Long-term PSA-free survival and castration-free survival with delayed antiandrogen therapy in patients with one versus two or more positive nodes at prostatectomy., Lodde M, Lacombe L, Naselli A, Puppo P, Mian M, Fradet Y, World journal of urology, 2012, 10.1007/s00345-012-0827-z
  • Banking of fresh-frozen prostate tissue using the alternate mirror image protocol: methods, validation, and impact on the pathological prognostic parameters in radical prostatectomy., Brimo F, Sircar K, Chevalier S, Saad F, Lacombe L, Têtu B, Scarlata E, Aprikian A, Cell and tissue banking, 2011, 10.1007/s10561-011-9284-y
  • The impact of germline genetic variations in hydroxysteroid (17-beta) dehydrogenases on prostate cancer outcomes after prostatectomy., Audet-Walsh É, Bellemare J, Lacombe L, Fradet Y, Fradet V, Douville P, Guillemette C, Lévesque É, European urology, 2011, 10.1016/j.eururo.2011.12.021
  • Northeastern Section of the American Urological Association 63(rd) Annual Meeting, New Orleans, Louisiana October 26 - 30, 2011 Scientific Program., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • Age ≥ 80 years is independently associated with survival outcomes after radical cystectomy: results from the Canadian Bladder Cancer Network Database., Fairey AS, Kassouf W, Aprikian AG, Chin JL, Izawa JI, Fradet Y, Lacombe L, Rendon RA, Bell D, Cagiannos I, Drachenberg DE, Lattouf JB, Estey EP, Urologic oncology, 2011, 10.1016/j.urolonc.2011.07.014
  • Deletions of the androgen-metabolizing UGT2B genes have an effect on circulating steroid levels and biochemical recurrence after radical prostatectomy in localized prostate cancer., Nadeau G, Bellemare J, Audet-Walsh É, Flageole C, Huang SP, Bao BY, Douville P, Caron P, Fradet Y, Lacombe L, Guillemette C, Lévesque E, The Journal of clinical endocrinology and metabolism, 2011, 10.1210/jc.2011-1049
  • 2011 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011
  • SRD5A polymorphisms and biochemical failure after radical prostatectomy., Audet-Walsh E, Bellemare J, Nadeau G, Lacombe L, Fradet Y, Fradet V, Huang SP, Bao BY, Douville P, Girard H, Guillemette C, Lévesque E, European urology, 2011, 10.1016/j.eururo.2011.06.020
  • Progression from high-grade prostatic intraepithelial neoplasia to cancer: a randomized trial of combination vitamin-E, soy, and selenium., Fleshner NE, Kapusta L, Donnelly B, Tanguay S, Chin J, Hersey K, Farley A, Jansz K, Siemens DR, Trpkov K, Lacombe L, Gleave M, Tu D, Parulekar WR, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2011, 10.1200/jco.2010.32.0994
  • Radical cystectomy for the treatment of T1 bladder cancer: the Canadian Bladder Cancer Network experience., Chalasani V, Kassouf W, Chin JL, Fradet Y, Aprikian AG, Fairey AS, Estey E, Lacombe L, Rendon R, Bell D, Cagiannos I, Drachenberg D, Lattouf JB, Izawa JI, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2011, 10.5489/cuaj.10040
  • Dose-dependent antihypertensive efficacy and tolerability of perindopril in a large, observational, 12-week, general practice-based study., Tsoukas G, Anand S, Yang K, CONFIDENCE Investigators, American journal of cardiovascular drugs : drugs, devices, and other interventions, 2011, 10.2165/11587000-000000000-00000
  • Contemporary outcomes of 2287 patients with bladder cancer who were treated with radical cystectomy: a Canadian multicentre experience., Yafi FA, Aprikian AG, Chin JL, Fradet Y, Izawa J, Estey E, Fairey A, Rendon R, Cagiannos I, Lacombe L, Lattouf JB, Bell D, Drachenberg D, Kassouf W, BJU international, 2010, 10.1111/j.1464-410x.2010.09912.x
  • Improved cancer specific-survival in patients with carcinoma invading bladder muscle expressing cyclo-oxygenase-2., Aziz A, Lessard A, Moore K, Hovington H, Latulippe E, Larue H, Fradet Y, Lacombe L, BJU international, 2010, 10.1111/j.1464-410x.2010.09909.x
  • 2010 NS-AUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Evaluation of fluorodeoxyglucose positron-emission tomography with computed tomography for staging of urothelial carcinoma., Lodde M, Lacombe L, Friede J, Morin F, Saourine A, Fradet Y, BJU international, 2010, 10.1111/j.1464-410x.2010.09212.x
  • 2010 CUA Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010
  • Canadian guidelines for treatment of non-muscle invasive bladder cancer: a focus on intravesical therapy., Kassouf W, Kamat AM, Zlotta A, Bochner BH, Moore R, So A, Izawa J, Rendon RA, Lacombe L, Aprikian AG, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2010, 10.5489/cuaj.10051
  • Effect of dutasteride on the risk of prostate cancer., Andriole GL, Bostwick DG, Brawley OW, Gomella LG, Marberger M, Montorsi F, Pettaway CA, Tammela TL, Teloken C, Tindall DJ, Somerville MC, Wilson TH, REDUCE Study Group, The New England journal of medicine, 2010, 10.1056/nejmoa0908127
  • Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer., Lodde M, Lacombe L, Fradet Y, Urology, 2010, 10.1016/j.urology.2009.12.057
  • Clinical benefits of a multivariate prediction model for bladder cancer: a decision analytic approach., Vickers AJ, Cronin AM, Kattan MW, Gonen M, Scardino PT, Milowsky MI, Dalbagni G, Bochner BH, International Bladder Cancer Nomogram Consortium, Cancer, 2009, 10.1002/cncr.24615
  • 2009 AUA-NS Abstracts., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer., Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, Fradet Y, International journal of cancer, 2009, 10.1002/ijc.24503
  • Denosumab in men receiving androgen-deprivation therapy for prostate cancer., Smith MR, Egerdie B, Hernández Toriz N, Feldman R, Tammela TL, Saad F, Heracek J, Szwedowski M, Ke C, Kupic A, Leder BZ, Goessl C, Denosumab HALT Prostate Cancer Study Group, The New England journal of medicine, 2009, 10.1056/nejmoa0809003
  • Carcinoma of the upper urinary tract: predictors of survival and competing causes of mortality., Inman BA, Tran VT, Fradet Y, Lacombe L, Cancer, 2009, 10.1002/cncr.24339
  • 2009 CUA Abstracts, Al Mandil M, Ruwali A, Boucher A, Cloutier J, Lebel S, Hamel M, Lamontagne P, Bolduc S, McLorie G, Hodges S, Atala A, Bénard F, Casey R, Carrier S, Haider M, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2009 CUA Abstracts, Yafi F, Aprikian A, Tanguay S, Kassouf W, Wong C, Spaliviero M, Araki M, Schultz T, Mador D, Hobart M, Hill L, Marks L, Gittelman M, Volinn W, Luke P, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • 2009 CUA Abstracts, Saad F, Smith M, Egerdie B, Feldman R, Tammela T, Heracek J, Szwedowski M, Ke C, Kupic A, Leder B, Goessl C, Pinthus J, Farrokhyar F, Hassouna M, Kassouf W, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009
  • Early detection of prostate cancer local recurrence by urinary prostate-specific antigen., Bolduc S, Inman BA, Lacombe L, Fradet Y, Tremblay RR, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1074
  • Bladder tumor infiltrating mature dendritic cells and macrophages as predictors of response to bacillus Calmette-Guérin immunotherapy., Ayari C, LaRue H, Hovington H, Decobert M, Harel F, Bergeron A, Têtu B, Lacombe L, Fradet Y, European urology, 2009, 10.1016/j.eururo.2009.01.040
  • Follow-up guidelines after radical or partial nephrectomy for localized and locally advanced renal cell carcinoma., Kassouf W, Siemens R, Morash C, Lacombe L, Jewett M, Goldenberg L, Chin J, Chetner M, Wood CG, Tanguay S, Aprikian AG, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2009, 10.5489/cuaj.1028
  • PROGRAMME SCIENTIFIQUE : Samedi, le 15 novembre 2008, Session scientifique VIII, Fahmy N, Amin M, Jeyaganth S, Kassouf W, Tanguay S, Steinberg J, Aprikian A, Cury J, Karsenty G, Andrieu C, Rocchi P, Bladou F, Chevallier S, Aprikian A, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • PROGRAMME SCIENTIFIQUE : Vendredi, le 14 novembre 2008, Session scientifique V, Aziz A, Moore K, Blackburn F, Lessard A, Hovington H, Harel F, Larue H, Lacombe L, Fradet Y, Baillargeon-Gagné S, Jeldres C, Letendre J, Asker A, Fradet Y, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • Maintenance bacillus Calmette-Guérin in high-risk nonmuscle-invasive bladder cancer: how much is enough?, Decobert M, LaRue H, Harel F, Meyer F, Fradet Y, Lacombe L, Cancer, 2008, 10.1002/cncr.23627
  • An adjuvant autologous therapeutic vaccine (HSPPC-96; vitespen) versus observation alone for patients at high risk of recurrence after nephrectomy for renal cell carcinoma: a multicentre, open-label, randomised phase III trial., Wood C, Srivastava P, Bukowski R, Lacombe L, Gorelov AI, Gorelov S, Mulders P, Zielinski H, Hoos A, Teofilovici F, Isakov L, Flanigan R, Figlin R, C-100-12 RCC Study Group, Lancet (London, England), 2008, 10.1016/s0140-6736(08)60697-2
  • Canadian Urological Association, 63rd Annual Meeting, Edmonton, AB, June 22-25, 2008., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2008
  • Tissue factor expression correlates with disease-specific survival in patients with node-negative muscle-invasive bladder cancer., Patry G, Hovington H, Larue H, Harel F, Fradet Y, Lacombe L, International journal of cancer, 2008, 10.1002/ijc.23240
  • Substratification of high-risk localised prostate cancer treated by radical prostatectomy., Lodde M, Harel F, Lacombe L, Fradet Y, World journal of urology, 2008, 10.1007/s00345-008-0252-5
  • PROGRAMME SCIENTIFIQUE * SCIENTIFIC PROGRAM Association des urologues du QUébec * Qué Urological Association Congrès annuel * Annual Meeting 9 au 11 novembre 2007 * November 9-11, 2007 Hôtel Hyatt Regency Montréal Centre-Ville, Montréal PQ., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • Urinary PSA: a potential useful marker when serum PSA is between 2.5 ng/mL and 10 ng/mL., Bolduc S, Lacombe L, Naud A, Grégoire M, Fradet Y, Tremblay RR, Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007, 10.5489/cuaj.444
  • Canadian Urological Association 62nd Annual Meeting, Quebec City, QC, June 24-27, 2006., , Canadian Urological Association journal = Journal de l'Association des urologues du Canada, 2007
  • PD-L1 (B7-H1) expression by urothelial carcinoma of the bladder and BCG-induced granulomata: associations with localized stage progression., Inman BA, Sebo TJ, Frigola X, Dong H, Bergstralh EJ, Frank I, Fradet Y, Lacombe L, Kwon ED, Cancer, 2007, 10.1002/cncr.22588
  • Prostatic intraepithelial neoplasia in TURP specimens and subsequent prostate cancer., Meyer F, Têtu B, Bairati I, Lacombe L, Fradet Y, The Canadian journal of urology, 2006
  • Polymorphisms of the human NRAMP1 gene are associated with response to bacillus Calmette-Guerin immunotherapy for superficial bladder cancer., Decobert M, Larue H, Bergeron A, Harel F, Pfister C, Rousseau F, Lacombe L, Fradet Y, The Journal of urology, 2006, 10.1016/s0022-5347(05)00653-1
  • Psychological functioning associated with prostate cancer: cross-sectional comparison of patients treated with radiotherapy, brachytherapy, or surgery., Hervouet S, Savard J, Simard S, Ivers H, Laverdière J, Vigneault E, Fradet Y, Lacombe L, Journal of pain and symptom management, 2005, 10.1016/j.jpainsymman.2005.05.011
  • Insomnia in men treated with radical prostatectomy for prostate cancer., Savard J, Simard S, Hervouet S, Ivers H, Lacombe L, Fradet Y, Psycho-oncology, 2005, 10.1002/pon.830
  • Insulin-like growth factor binding protein 2: an androgen-dependent predictor of prostate cancer survival., Inman BA, Harel F, Audet JF, Meyer F, Douville P, Fradet Y, Lacombe L, European urology, 2005, 10.1016/j.eururo.2004.12.015
  • Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer., Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Zheng M, Zoledronic Acid Prostate Cancer Study Group, Journal of the National Cancer Institute, 2004, 10.1093/jnci/djh141
  • Expression of p21 cell cycle protein is an independent predictor of response to salvage radiotherapy after radical prostatectomy., Rigaud J, Tiguert R, Decobert M, Hovington H, Latulippe E, Laverdiere J, Larue H, Lacombe L, Fradet Y, The Prostate, 2004, 10.1002/pros.10329
  • Routine nasogastric tubes are not required following cystectomy with urinary diversion: a comparative analysis of 430 patients., Inman BA, Harel F, Tiguert R, Lacombe L, Fradet Y, The Journal of urology, 2003, 10.1097/01.ju.0000092500.68655.48
  • Neoadjuvant hormone therapy before salvage radiotherapy for an increasing post-radical prostatectomy serum prostate specific antigen level., Tiguert R, Rigaud J, Lacombe L, Laverdière J, Fradet Y, The Journal of urology, 2003, 10.1097/01.ju.0000075351.51838.b3
  • A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma., Saad F, Gleason DM, Murray R, Tchekmedyian S, Venner P, Lacombe L, Chin JL, Vinholes JJ, Goas JA, Chen B, Zoledronic Acid Prostate Cancer Study Group, Journal of the National Cancer Institute, 2002, 10.1093/jnci/94.19.1458
  • Does the potassium stimulation test predict cystometric, cystoscopic outcome in interstitial cystitis?, Grégoire M, Liandier F, Naud A, Lacombe L, Fradet Y, The Journal of urology, 2002, 10.1016/s0022-5347(05)64678-2
  • Duration of neoadjuvant androgen deprivation therapy before radical prostatectomy and disease-free survival in men with prostate cancer., Meyer F, Bairati I, Bédard C, Lacombe L, Têtu B, Fradet Y, Urology, 2001, 10.1016/s0090-4295(01)01245-6
  • Expression of p21 predicts PSA failure in locally advanced prostate cancer treated by prostatectomy., Lacombe L, Maillette A, Meyer F, Veilleux C, Moore L, Fradet Y, International journal of cancer, 2001, 10.1002/1097-0215(20010520)95:3<135::aid-ijc1023>3.0.co;2-3
  • Can biological markers predict recurrence and progression of superficial bladder cancer?, Fradet Y, Lacombe L, Current opinion in urology, 2000, 10.1097/00042307-200009000-00013
  • Tumorigenic pathways in low-stage bladder cancer based on p53, MDM2 and p21 phenotypes., Pfister C, Larue H, Moore L, Lacombe L, Veilleux C, Tetu B, Meyer F, Fradet Y, International journal of cancer, 2000, 10.1002/(sici)1097-0215(20000120)89:1<100::aid-ijc16>3.0.co;2-q
  • Neoadjuvant hormonal therapy before radical prostatectomy and risk of prostate specific antigen failure., Meyer F, Moore L, Bairati I, Lacombe L, Têtu B, Fradet Y, The Journal of urology, 1999, 10.1016/s0022-5347(05)68092-5
  • Predictive value of cell cycle markers p53, MDM2, p21, and Ki-67 in superficial bladder tumor recurrence., Pfister C, Moore L, Allard P, Larue H, Lacombe L, Têtu B, Meyer F, Fradet Y, Clinical cancer research : an official journal of the American Association for Cancer Research, 1999
  • Prognostic value of the proliferative index determined by Ki-67 immunostaining in superficial bladder tumors., Pfister C, Lacombe L, Vezina MC, Moore L, Larue H, Têtu B, Meyer F, Fradet Y, Human pathology, 1999, 10.1016/s0046-8177(99)90067-9
  • Deletions of the INK4A gene in superficial bladder tumors. Association with recurrence., Orlow I, LaRue H, Osman I, Lacombe L, Moore L, Rabbani F, Meyer F, Fradet Y, Cordon-Cardo C, The American journal of pathology, 1999, 10.1016/s0002-9440(10)65105-x
  • Male urethral carcinoma: analysis of treatment outcome., Dalbagni G, Zhang ZF, Lacombe L, Herr HW, Urology, 1999, 10.1016/s0090-4295(98)00659-1
  • Blood management and radical retropubic prostatectomy: Quebec experience., Lacombe L, Fradet Y, The Canadian journal of urology, 1999
  • Female urethral carcinoma: an analysis of treatment outcome and a plea for a standardized management strategy., Dalbagni G, Zhang ZF, Lacombe L, Herr HW, British journal of urology, 1998, 10.1046/j.1464-410x.1998.00878.x
  • Genotypic and phenotypic characterization of the histoblood group ABO(H) in primary bladder tumors., Orlow I, Lacombe L, Pellicer I, Rabbani F, Delgado R, Zhang ZF, Szijan I, Cordón-Cardó C, International journal of cancer, 1998, 10.1002/(sici)1097-0215(19980316)75:6<819::aid-ijc1>3.0.co;2-y
  • Cigarette smoking and chromosome 9 alterations in bladder cancer., Zhang ZF, Shu XM, Cordon-Cardo C, Orlow I, Lu ML, Millon TV, Cao PQ, Connolly-Jenks C, Dalbagni G, Lianes P, Lacombe L, Reuter VE, Scher H, Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 1997
  • [Clinical value of the study of proliferation and cell activation antigens with flow cytometry in bladder cancer]., Lacombe L, Gauthier J, Lafleur L, Fradet Y, Progres en urologie : journal de l'Association francaise d'urologie et de la Societe francaise d'urologie, 1996
  • Overexpression of p53 protein in a high-risk population of patients with superficial bladder cancer before and after bacillus Calmette-Guérin therapy: correlation to clinical outcome., Lacombe L, Dalbagni G, Zhang ZF, Cordon-Cardo C, Fair WR, Herr HW, Reuter VE, Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1996, 10.1200/jco.1996.14.10.2646
  • Microsatellite instability and deletion analysis of chromosome 10 in human prostate cancer., Lacombe L, Orlow I, Reuter VE, Fair WR, Dalbagni G, Zhang ZF, Cordon-Cardo C, International journal of cancer, 1996, 10.1002/(sici)1097-0215(19960422)69:2<110::aid-ijc7>3.0.co;2-3
  • Analysis of p21WAF1/CIP1 in primary bladder tumors., Lacombe L, Orlow I, Silver D, Gerald WL, Fair WR, Reuter VE, Cordon-Cardo C, Oncology research, 1996
  • Deletion of the p16 and p15 genes in human bladder tumors., Orlow I, Lacombe L, Hannon GJ, Serrano M, Pellicer I, Dalbagni G, Reuter VE, Zhang ZF, Beach D, Cordon-Cardo C, Journal of the National Cancer Institute, 1995, 10.1093/jnci/87.20.1524
  • Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression., Gruis NA, Weaver-Feldhaus J, Liu Q, Frye C, Eeles R, Orlow I, Lacombe L, Ponce-Castaneda V, Lianes P, Latres E, The American journal of pathology, 1995
  • p27Kip1: chromosomal mapping to 12p12-12p13.1 and absence of mutations in human tumors., Ponce-Castañeda MV, Lee MH, Latres E, Polyak K, Lacombe L, Montgomery K, Mathew S, Krauter K, Sheinfeld J, Massague J, Cancer research, 1995
  • Chromosome 9 allelic losses and microsatellite alterations in human bladder tumors., Orlow I, Lianes P, Lacombe L, Dalbagni G, Reuter VE, Cordon-Cardo C, Cancer research, 1994

Contribution à l'enseignement aux cycles supérieurs

Direction et personnes-ressources

Vice-décanat à la recherche et aux études supérieures
Pavillon Ferdinand-Vandry
Université Laval
1050, avenue de la Médecine,  local 4645
Québec, Québec G1V 0A6
Canada

Renseignements - Secrétariat :
vdres@fmed.ulaval.ca
Téléphone 418 656-2690

Jacques Simard
Vice-doyen à la recherche et aux études supérieures
vice-doyen.recherche-et-etudes-superieures@fmed.ulaval.ca

Louise Laperrière
Adjointe au vice-doyen à la recherche et aux études supérieures
louise.laperriere@fmed.ulaval.ca 

Volet recherche
Gestion financière
Volet études aux cycles supérieurs